UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
Date
of Report (Date of earliest event reported)
|
December
31, 2008
|
||||
NovaBay
Pharmaceuticals, Inc.
|
|||||
(Exact
name of registrant as specified in its charter)
|
|||||
California
|
001-33678
|
68-0454536
|
|||
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|||
5980
Horton Street, Suite 550, Emeryville, CA
|
94608
|
||||
(Address
of principal executive offices)
|
(Zip
Code)
|
||||
Registrant’s
telephone number, including area code
|
(510)
899-8800
|
||||
Not
Applicable
|
|||||
(Former
name or former address, if changed since last
report)
|
£
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
£
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
£
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
£
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|